GlassScriptPhysician profile
Lauren M Maiorini
NPI 1790039014
$1,554.94
in general payments reported to CMS, 2019-2025
21 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.98 · 2024: $351 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.50 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $264.06 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $156.38 | 2025 | |
| Novo Nordisk INC | $124.66 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $106.60 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $97.93 | 2023-2025 | |
| Esperion Therapeutics, INC. | $74.44 | 2024-2025 | Nexletol |
| Dexcom, INC. | $70.04 | 2024-2025 | Dexcom G6 Transmitter |
| Madrigal Pharmaceuticals | $54.27 | 2025 | Rezdiffra |
| Xeris Pharmaceuticals, INC. | $39.86 | 2025 | Gvoke Hypopen |
| Cvrx, INC. | $38.36 | 2024 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $37.56 | 2024-2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $33.50 | 2025 | |
| Lundbeck LLC | $30.84 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $27.27 | 2025 | Verquvo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.97 | 2025 | |
| Beta Bionics, INC. | $24.18 | 2024 | Ilet Bionic Pancreas |
| Ionis Pharmaceuticals, INC. | $21.84 | 2025 | Tryngolza |
| Insulet Corporation | $21.00 | 2025 | Omnipod |
| Boston Scientific Corporation | $19.92 | 2025 | Watchman Flx |
| Daiichi Sankyo INC. | $18.76 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Maiorini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.